Conditions: Advanced/Metastatic Breast Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 63
Healthy volunteers: no

Brief summary:
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Capecitabine intervention 2: Sunitinib
Intervention descriptions: intervention 1: Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles intervention 2: Sunitinib 37.5 mg daily, continuous dosing

Protocol document: